Latest Breaking News On - Linear energy transfer - Page 7 : comparemela.com

Oncoinvent AS: Oncoinvent Announces Advancement of Radspherin to Fourth Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Ovarian Cancer Patients

Oncoinvent AS: Oncoinvent Announces Advancement of Radspherin to Fourth Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Ovarian Cancer Patients
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Jana alfheimCourtney turianoKostenloser wertpapierhandelSafety monitoring committeeLinear energy transferChief executive officerStern investor relations

Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round

Press release content from Business Wire. The AP news staff was not involved in its creation. Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round June 29, 2021 GMT OSLO, Norway (BUSINESS WIRE) Jun 29, 2021 Norway Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, announced today that the company has raised NOK 250 million in an oversubscribed pre-IPO financing round syndicated by existing investors Hadean Ventures, Geveran, RADFORSK Investeringsstiftelse, Sundt, Must Invest, Canica, MP Pensjon and Watrium. The net proceeds from the Private Placement are expected to ensure financing past end of 2023 for its lead product candidate Radspherin®, including financing of two clinical phase 2A studies (in ovarian cancer and colorectal cancer) as well as the advancement of the company’s proprietary targeted radiotherapy candidates. Oncoinvent has raised a total of NOK 535 million to date.

Jana alfheimCourtney turianoRoyh larsenIngrid teigland akayLinear energy transferHadean venturesMust investPrivate placementBoard chairTeigland akayManaging partnerChief executiveStern investorNorway oncoinventBusiness wireநேரியல் ஆற்றல் பரிமாற்றம்

Norway Oncoinvent AS: Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round

Norway Oncoinvent AS: Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company to initiate the next phase of clinical development of its lead product candidate Radspherin Norway Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, announced today that the company has raised NOK 250 million in an oversubscribed pre-IPO financing round syndicated by existing investors Hadean Ventures, Geveran, RADFORSK Investeringsstiftelse, Sundt, Must Invest, Canica, MP Pensjon and Watrium. The net proceeds from the Private Placement are expected to ensure financing past end of 2023 for its lead product candidate Radspherin, including financing of two clinical phase 2A studies (in ovarian cancer and colorectal cancer) as well as the advancement of the company s proprietary targeted radiotherapy

Jana alfheimCourtney turianoKostenloser wertpapierhandelRoyh larsenIngrid teigland akayLinear energy transferHadean venturesMust investPrivate placementBoard chairTeigland akayManaging partnerChief executive officerStern investor relationsநேரியல் ஆற்றல் பரிமாற்றம்வேண்டும் முதலீடு

Following a Year of Outstanding Performance, Oncoinvent Aims to Raise NOK 150-200 Million to Move Into Efficacy Studies With Radspherin®

Following a Year of Outstanding Performance, Oncoinvent Aims to Raise NOK 150-200 Million to Move Into Efficacy Studies With Radspherin®
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomJana alfheimRoyh larsenIngrid teigland akayLinear energy transferFinancial servicesArctic securitiesJoint global coordinatorsJoint bookrunnersPrivate placementHadean venturesMust investTeigland akayManaging partnerSecurities act

Oncoinvent AS: Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin in the Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients

(0) 7MBq dose of Radspherin determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that the Safety Monitoring Committee for the RAD-18-002 clinical trial has concluded that the 7 MBq dose of Radspherin to be safe and has approved initiation of the repeated injection and expansion cohorts of the ongoing RAD-18-002 Phase 1 study in colorectal cancer patients suffering from peritoneal carcinomatosis. Radspherin, an a-emitting radionuclide therapy designed for treatment of metastatic cancers in body cavities, is also being evaluated in an ongoing Phase 1 study in ovarian cancer patients with peritoneal carcinomatosis.

Jana alfheimCourtney turianoKostenloser wertpapierhandelMbq radspherinSafety monitoring committeeLinear energy transferChief executive officerChief financial officerStern investor relationsபாதுகாப்பு கண்காணிப்பு குழுநேரியல் ஆற்றல் பரிமாற்றம்தலைமை நிர்வாகி அதிகாரிதலைமை நிதி அதிகாரிகடுமையான முதலீட்டாளர் உறவுகள்